德尔塔
您当前所在位置:首页 > 最新产品 > 热销推荐

「同位素标记抑制剂」CAS:1216432-56-2|Hydroxychloroquine-d4-1 sulfate

发布时间:2025-06-13     作者:德尔塔生物   分享到:

【产品介绍】:

生物活性:Hydroxychloroquine-d4-1 (sulfate) is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].
IC50 & Target:Plasmodium
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Hydroxychloroquine-d4-1 sulfate 相关抗体:
IRF3 Antibody
Toll-Like Receptor 4 Antibody
Toll-Like Receptor 3 Antibody
TLR2 Antibody
Toll-Like Receptor 2 Antibody (YA1932)
TRIF Antibody (YA2263)
TIRAP Antibody (YA2589)
Toll-Like Receptor 9 Antibody (YA3321)
Toll-Like Receptor 7 Antibody (YA2514)
Toll-Like Receptor 5 Antibody (YA3265)
分子量:437.97
Formula:C18H24D4ClN3O5S
CAS 号:1216432-56-2
非标记 CAS:747-36-4
性状:固体
颜色:White to off-white
中文名称:羟氯喹 d4 (硫酸盐) (烷基上氘)
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:4°C, sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
纯度 & 产品资料
纯度: ≥98.0%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4(1):6.
 [Content Brief]
[3]. Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85(3):429-40.
 [Content Brief]
[4]. Yao X, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237.
 [Content Brief]